Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CEO Jeffrey M. Leiden sold 99,563 shares of the stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $156.99, for a total transaction of $15,630,395.37. Following the completion of the sale, the chief executive officer now directly owns 176,747 shares of the company’s stock, valued at approximately $27,747,511.53. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Vertex Pharmaceuticals Incorporated (VRTX) traded up $1.28 on Wednesday, reaching $156.99. 1,270,000 shares of the company were exchanged, compared to its average volume of 1,540,000. The firm has a market cap of $39,700.00, a price-to-earnings ratio of 201.27, a price-to-earnings-growth ratio of 1.86 and a beta of 1.58. Vertex Pharmaceuticals Incorporated has a 1-year low of $79.78 and a 1-year high of $167.85. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.14 and a current ratio of 3.28.
Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.49. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The business had revenue of $578.20 million during the quarter, compared to analyst estimates of $522.07 million. During the same period last year, the business earned $0.16 EPS. The business’s revenue was up 39.7% on a year-over-year basis. analysts forecast that Vertex Pharmaceuticals Incorporated will post 0.76 earnings per share for the current year.
Several equities research analysts have recently issued reports on VRTX shares. DA Davidson started coverage on shares of Vertex Pharmaceuticals in a research report on Friday, September 29th. They issued a “buy” rating and a $200.00 price objective for the company. BTIG Research started coverage on shares of Vertex Pharmaceuticals in a research report on Friday, September 29th. They issued a “buy” rating and a $200.00 price objective for the company. BMO Capital Markets reissued a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Wednesday, September 27th. Maxim Group reissued a “buy” rating and issued a $195.00 price objective on shares of Vertex Pharmaceuticals in a research report on Thursday, October 26th. Finally, Royal Bank of Canada reissued a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, twenty-five have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $175.89.
TRADEMARK VIOLATION WARNING: This piece was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2018/01/17/insider-selling-vertex-pharmaceuticals-incorporated-vrtx-ceo-sells-99563-shares-of-stock.html.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.